Non-profit organisation I-MAK is waging a global challenge against what it sees as invalid pharmaceutical patents, with access to life-saving drugs its main priority. LSIPR speaks to co-founder Tahir Amin to find out more.
More than 85% of Americans diagnosed with chronic hepatitis C will not receive treatment this year. It’s the same story the world over—the UK is rationing these drugs and France also has problems. These are the claims of Tahir Amin, co-founder of non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK).
Why are people not receiving the life-saving treatments they need? Partly because of skyrocketing drug prices and anti-competitive strategies by big pharma, claims Amin.
The non-profit foundation is determined to increase global access to affordable life-saving medication and, to do so, I-MAK plans to try to improve the patent system.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
I-MAK, Tahir Amin, sofosvbuvir, access to medicine, generic competition, chronic hepatitis , Gilead, public interest, patent filings, drug pricing, invalid
